Adrenomed key facts
as of Oct 2026- Developer of clinical-stage pharmaceutical products designed to improve vascular integrity.
- Adrenomed is valued at approximately $133.9M as of Oct 2026 (last reported valuation).
- It has raised $61.3M; the latest was Later Stage VC ($770K) in May 2025.
- Notable investors include VU Venture Partners, Brandenburg Kapital, HBM Partners, Wellington Partners, KfW Group — 10 tracked in total.
- Status: Privately Held (backing).
Adrenomed's last reported valuation, Mar 2021. Nothing priced has surfaced since.
- ·Watch Adrenomed: the Monday email on marks, rounds and moves
Adrenomed funding rounds
No funding rounds for Adrenomed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Adrenomed valuation
Adrenomed's last reported valuation was $134 million in Mar 2021. No priced round, secondary trade or fund mark has surfaced since.
Adrenomed investors
10 investors are on record for Adrenomed, including VU Venture Partners, Brandenburg Kapital, HBM Partners and Wellington Partners.
About Adrenomed
Developer of clinical-stage pharmaceutical products designed to improve vascular integrity. The company's products use biomarker-guided monoclonal antibody therapies that offer a causative, safe treatment for acute circulatory failure, enabling doctors to reduce vascular leakage, stabilize the circulation, and lower mortality.
- Sector
- Healthcare
- HQ
- Hennigsdorf, Germany
- Founded
- 2009
- Employees
- 18
- Website
- adrenomed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.